Why become a Contributing Partner?

Partnering with us accelerates the development of life-saving technologies that improve health and economic opportunities for millions, particularly the world’s most vulnerable populations.

Contributing Partners (CPs) also benefit directly from their support by:

Shaping research and funding priorities

CPs gain influence over the strategic direction and practical execution of the research agenda, ensuring alignment with their own institutional goals:

• Informing strategic direction: CPs inform the strategic direction and research funding priorities of Global Health EDCTP3, including the design of its work programmes.
• Co-designing call topic texts: For CPs that provide Financial Contributions, they can take part in the design of the call topic texts they fund.
• Observer status: CPs who are Financial Contribution providers and are not part of any applying consortium may be granted observer status in the evaluation process of the calls they have funded and be involved in the assessment of project reports and deliverables.

Financial and strategic leverage (co-funding)

Contributing Partners benefit from a highly effective mechanism to multiply the value, scale, and impact of their investments:

• Improving cost-effectiveness: Partnering enhances the coherence, complementarity, and alignment of investments around the common Strategic Research and Innovation Agenda (SRIA).
• Leveraging additional EU funds: Contributions from CPs allow Global Health EDCTP3 to leverage up to €400 million of EU funds. This effectively increases the Global Health EDCTP3 overall budget, enabling the funding of more and larger projects.

Improving ESG performance and corporate reputation

For private entities, involvement as a CP offers substantial benefits related to Environmental, Social, and Governance (ESG) performance:

• Demonstrating ethical leadership: Participation demonstrates ethical leadership, responsible innovation, and a commitment to inclusive healthcare.
• Recognised by investors and other stakeholders: Efforts such as prioritising high-burden diseases in low- and middle-income countries, promoting access plans, and encouraging diversity in clinical trials are recognised by ESG ratings agencies, investors, and accountability organisations like the Access to Medicines Foundation.
• Strengthening reputation: Engagement helps strengthen corporate reputation, build trust with stakeholders and governments, and boost staff morale by aligning company objectives with global societal goals.